Gene Therapy of Cancer

2nd Edition

Translational Approaches from Preclinical Studies to Clinical Implementation

Editors: Stanton Gerson Edmund Lattime Stanton Gerson
Print ISBN: 9780124375512
eBook ISBN: 9780080491363
Imprint: Academic Press
Published Date: 26th February 2002
Page Count: 534
270.00 + applicable tax
205.00 + applicable tax
260.00 + applicable tax
165.00 + applicable tax
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer.

Key Features

Key Features

  • Provides in-depth description of targeted systems and treatment strategies
  • Explains the underlying cancer biology necessary for understanding a given therapeutic approach
  • Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses
  • Presents translational focus with emphasis on requirements for clinical implementation
  • Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference


Oncologists, molecular geneticists, and hematologists.

Table of Contents

Contributors Preface Part I Vectors for Gene Therapy of Cancer

1. Retroviral Vector Design for Cancer Gene Therapy I. Introduction II. Applications for Retroviral Vectors in Oncology III. Biology of Retroviruses IV. Principles of Retroviral Vector Systems V. Advances in Retroviral Vector Tailoring VI. Outlook References 2. Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy I. Introduction II. Advantages and Disadvantages of Infectious, Viral-Based Vectors for Human Gene Therapy III. Rationale for Considering Noninfectious, Plasmid-Based Expression Systems IV. Gene Transfer Technologies for Plasmid-Based Vectors: Preclinical Models and Clinical Cancer Gene Therapy Trials V. Plasmid Expression Vectors VI. Future Directions References 3. Parvovirus Vectors for the Gene Therapy of Cancer I. Introduction II. Biology of Parvoviridae and Vector Development III. Applications of Recombinant Parvovirus Vectors to Cancer Gene Therapy IV. Perspectives, Problems, and Future Considerations References 4. Antibody-Targeted Gene Therapy I. Introduction II. Background: Monoclonal Antibodies and Cancer Therapy III. Recent Advances: Monoclonal-Antibody-Mediated Targeting and Cancer Gene Therapy IV. Future Directions References 5. Ribozymes in Cancer Gene Therapy I. Introduction II. Ribozyme Structures and Functions III. Cancer Disease Models for Ribozyme Application IV. Challenges and Future Directions References 6. The Advent of Lentiviral Vectors: Prospects for Cancer Therapy I. Introduction II. Structure and Function of Lentiviruses III. Features that Distinguish Lentiviral


No. of pages:
© Academic Press 2002
Academic Press
eBook ISBN:
Hardcover ISBN:

About the Editor

Stanton Gerson

Stanton L Gerson is Director of the Case Comprehensive Cancer Center & the National Center for Regenerative Medicine at Case Western Reserve University and Director of University Hospitals Seidman Cancer Center in Cleveland. Dr. Gerson studies DNA repair, stem cells and cancer therapy. He showed that over-expression of the MGMT DNA repair gene could prevent cancer and that a mutant form of MGMT protects hematopoietic stem cells from chemotherapy using lentiviral gene therapy. He has interrogated MGMT, MMR and BER DNA repair pathways as targets for cancer therapy, and proposed that methoxyamine would block base excision repair used in combination with chemotherapy. Dr. Gerson also directed the initial use of mesenchymal stem cells (MSCs) in bone marrow transplantation & in gene therapy.

Affiliations and Expertise

Director of the Case Comprehensive Cancer Center and the National Center for Regenerative Medicine at Case Western Reserve University; Director of University Hospitals Seidman Cancer Center in Cleveland, OH.

Edmund Lattime

Edmund C. Lattime is Professor of Surgery at the Robert Wood Johnson Medical School and Deputy Director, The Cancer Institute of New Jersey. Dr. Lattime studies tumor immunology and immunotherapy focusing on the tumor-host interaction and the tumor microenvironment. While faculty at Sloan Kettering and then Thomas Jefferson University, his translational studies led to the development and Phase I testing of a novel Vaccinia-GMCSF construct designed to enhance the development of antitumor immunity via infection/transfection of the tumor microenvironment. Based on his mechanistic studies of immune escape mechanisms, his group recently developed and is testing a poxvirus-based immunization strategy, which uses antigen encoding poxvirus delivered to the tumor microenvironment, in patients with locally-advanced pancreatic cancer.

Affiliations and Expertise

The Cancer Institute of New Jersey, New Brunswick, U.S.A.

Stanton Gerson

Stanton L. Gerson received his M.D. at Harvard Medical School. He was a Resident in Medicine at the Hospital of the University of Pennsylvania, where he became a Fellow in Hematology-Oncology in 1980. He is an Edward Mallinckrodt Jr. Foundation Scholar, and is currently Chief, Division of Hematology/Oncology at Case Western Reserve University, where he has served since 1983. Dr. Gerson is a member of several major professional and scientific societies and is a principal investigator of funded grants for several philanthropic organizations. He is author or a contributor to over 200 research papers, abstracts, theses and book chapters. Since 1987, Dr. Gerson has been invited to be a guest lecturer at over 40 national and international conferences.

Affiliations and Expertise

Case Western Reserve University, Cleveland, Ohio, U.S.A.


@qu:" ...represents the 'state-of-the-art', describing the progress made to date in its written chapters. ...this book is a worthy addition to the laboratories and libraries serving the students, fellows and experienced researchers devoted to translating cancer gene therapy applications from laboratory to the bedside." @source—Robert E. Sobol, GenStar Therapeutics, Sidney Kimmel Cancer Center (2002)